Dr. Reck on Safety Data From the CheckMate-9LA Trial in Metastatic/Recurrent NSCLC
Martin Reck, MD, PhD, discusses safety data from the phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer.
Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses safety data from the phase 3 CheckMate-9LA trial in metastatic or recurrent non–small cell lung cancer (NSCLC).
Findings from the study suggest that the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) plus 2 cycles of platinum-doublet chemotherapy should be considered an option for this patient population.
However, it is an intensive regimen, says Reck. Moreover, treatment-emergent adverse effects (AEs) were observed more frequently with the experimental regimen compared with chemotherapy alone.
Treatment-related deaths occurred in 2% of patients in both arms.
Notably, the incidence of chemotherapy-related AEs including hematologic AEs was lower in the combination arm as patients received 2 cycles of chemotherapy versus 4, Reck concludes.
